immunology biosimilar
Scope
Date
~
-
Bio & Pharma
Celltrion gets OK partial approval for phase 3 of biosimilar in Europe
South Korean biopharmaceutical company Celltrion Inc. announced on Tuesday that it has received approval from the European Medicines Agency (EMA) fo...
Aug 22, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis seeks to buy Biogen biosimilar unit
Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea’s Samsung Group, seeks to buy a biosimilar business d...
Aug 02, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis enters US market for biosimilars of Humira
South Korea's biopharmaceutical company Samsung Bioepis, which was expected to struggle on the US market for biosimilars of Humira, the world's top-...
Jul 14, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare launches Humira biosimilar Yuflyma in US
South Korean biopharmaceutical company Celltrion Healthcare on Monday said it launched the day before on the US market Yuflyma, a biosimilar of the ...
Jul 04, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for approval in US for eye treatment biosimilar
South Korean biopharmaceutical company Celltrion Inc. on Friday said it applied for approval from the US Food and Drug Administration (FDA) for CT-P...
Jun 30, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion puts Takeda’s assets up for sale after 3 years
South Korea’s Celltrion Inc. has put its Japanese Takeda Pharmaceutical Co.'s primary care assets acquired in 2020 on sale as the biosimilar g...
Jun 18, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion wins phase 3 IND approval for Ocrevus biosimilar in US
South Korea's biopharmaceutical company Celltrion Inc. announced that it received on Thursday approval from the US Food and Drug Administration (FDA...
Jun 15, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion to expand biosimilar portfolio to 11 by 2025
South Korea's biopharmaceutical company Celltrion Inc. announced on Tuesday that it plans to beef up its portfolio by applying for regulatory approv...
Jun 13, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis to enhance biosimilar presence with Epysqli
FRANKFURT – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is looking to gain ground in the ra...
Jun 12, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion to develop Humira biosimilar oral medication with US firm
South Korea's biopharmaceutical company Celltrion Inc. announced on Monday that it has signed a contract with the US biotech firm Rani Therapeutics ...
Jun 05, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s Remsima SC praised in Europe as preferred biosimilar
MILAN – South Korea's biopharmaceutical company Celltrion Inc. is known in Europe for its biosimilar products such as autoimmune disease treat...
Jun 02, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion unveils phase 1 clinical data of Actemra biosimilar in Europe
South Korean biosimilar giant Celltrion Inc. revealed on Wednesday the highly anticipated clinical phase 1 data for its Actemra biosimilar, CT-P47, ...
May 31, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis gets approval to sell biosimilar in Europe
South Korea's Samsung Bioepis has received approval in Europe to sell a biosimilar of Soliris, a drug for the treatment of adult and children patien...
May 31, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion gets FDA approval for Humira biosimilar CT-P17
South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has obtained product approval from the US Food and Drug Adminis...
May 24, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for Phase 3 clinical trials in Europe for biosimilar
South Korea’s Celltrion Inc. is speeding up global clinical trials of its biosimilar of the multiple sclerosis (MS) treatment Ocrevus (active ...
May 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Biosimilar giant Celltrion to transform into drug developer
South Korean biosimilar giant Celltrion Group aims to transform into a drug developer by generating 40% of sales from new medicines by 2030 as it is...
Mar 29, 2023 (Gmt+09:00)
-
Mergers & Acquisitions
Celltrion eyes Baxter's arm as it gears up for M&As
Celltrion Inc., South Korea’s largest biosimilar maker, said on Tuesday it has studied a possible acquisition of the biopharma solutions unit ...
Mar 21, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis launches ARMD biosimilar drug in Germany, Canada
Samsung Bioepis Co., a South Korean biosimilar firm, announced on Sunday that it has recently launched a new biosimilar drug called SB11 for the tre...
Mar 06, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion ex-Chairman Seo set to return to management; group stocks rally
South Korea’s biosimilar giant Celltrion Group’s founder and Honorary Chairman Seo Jung-jin is readying to return to management just two...
Mar 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Prestige Bio's Herceptin biosimilar proves equivalence in clinical trials
Prestige Biopharma, a South Korean biopharmaceutical developer, said on Tuesday that the final analysis of phase 3 clinical trial on the anti-cancer...
Feb 08, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare launches anti-cancer biosimilar Vegzelma in Japan
Celltrion Healthcare Co. Ltd. said on Thursday that it launched Vegzelma, a biosimilar to the anti-cancer drug Avastin (active ingredient: bevacizum...
Jan 26, 2023 (Gmt+09:00)
-
Bio & Pharma
HK inno.N to introduce biosimilars for bone disease treatment from Spain
South Korea's biohealth company HK inno.N said on Wednesday that it has signed an agreement with Spanish pharmaceutical company mAbxience SA to intr...
Jan 26, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare lands biosimilar deal in Brazil for 2nd straight year
South Korea's Celltrion Healthcare Co. on Tuesday said that for the second straight year, it landed an order for infliximab, an antibody used to tre...
Jan 11, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion acquires approval to sell Vegzelma in Canada
South Korea's biosimilar heavyweight Celltrion Inc. has obtained permission from the Canadian health ministry to sell anticancer biosimilar Vegzelma...
Jan 05, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea's Alteogen signs $145 million tech export deal with Swiss company
South Korea's bio company Alteogen Inc. on Friday said it signed its fourth technology export contract since its 2018 development of the human recom...
Dec 30, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion wins trial against Regeneron for US patent lawsuit over biosimilar
South Korean biopharmaceutical company Celltrion Inc. announced Friday that it won its first trial against New York-based biotech giant Regeneron Ph...
Nov 18, 2022 (Gmt+09:00)
-
Healthcare
Celltrion targets digital healthcare sector with app
Celltrion Inc., South Korea’s biopharmaceutical giant, made a foray into the digital healthcare sector for its future growth by launching a sm...
Oct 05, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion wins sales approval for biosimilar Vegzelma in Japan
Celltrion Inc. secured Japan’s approval for sales of its cancer treatment biosimilar CT-P16, a move to help the South Korean biopharmaceutical...
Sep 27, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion gains sales approval for biosimilar Vegzelma in Europe
Celltrion Healthcare Co., South Korean biopharmaceutical giant Celltrion Inc.'s global marketing affiliate, said on Friday it has obtained the Europ...
Aug 19, 2022 (Gmt+09:00)
-
Earnings
Celltrion logs strong Q2 earnings powered by biosimilars
South Korea’s biopharmaceutical maker Celltrion Inc. on Friday reported strong quarterly earnings thanks to healthy demand for its biosimilar ...
Aug 05, 2022 (Gmt+09:00)